Notable Guests
AF
Abrahao Fecury
1x
AT
Alex Tatem
1x
BS
Bijan Salehizadeh
1x
BB
Brian Birnbaum
1x
CA
Christian Angermayer
1x
DM
David Maris
1x
DW
David Wells
1x
ED
Eli Dorf
1x
GK
Gaston Kroub
1x
IC
Ignacio Canto
1x
IK
Imran Khan
1x
JM
Jesse Morse
1x
JL
Jon Lensing
1x
JL
Jonah Lupton
1x
MH
Mansi Hukmani
1x
Recent Episodes
✨
Abrahão Fecury, CEO of Brazilian telehealth company Eles & Elas, discusses their growth.
Abrahao Fecury
✨
Raphaël Mazoyer, CEO of Finnrick, discusses their peptide testing database with over 10,000 results.
Raphael Mazoyer
✨
Dr. Jon Lensing, CEO of OpenLoop, discusses the white-label telehealth company.
Jon Lensing
✨
HIMS stock token surged on Robinhood due to the $BONER memecoin.
✨
Legal expert Gaston Kroub breaks down the FTC's lawsuit against Hims & Hers.
Gaston Kroub
✨
Discussed FDA leadership, including Heidi Overton's influence and Kyle Diamantis's role.
Bijan Salehizadeh
✨
Enhanced Games CEO Jonathan Stern discusses the upcoming games and telehealth platform.
✨
Dr. Alex Tatem shares his experience testifying before the FDA on peptides.
Alex Tatem
✨
Dr. Jesse Morse discusses the FDA's upcoming peptide review and market impact.
Jesse Morse
✨
Analyst Ryan MacDonald estimates the peptide market could exceed $30 billion.
✨
Board member David Wells explains his $1.2M Hims share purchase.
✨
Hedge fund manager Ignacio Canto views Hims as a 'Costco + Netflix' model.
✨
Hedge fund manager Imran Khan bought Hims shares during a market downturn.
Imran Khan
✨
Researcher Cremieux estimates half of America could be on GLP-1s by 2030.
✨
Empower Sleep founders discuss AI-powered sleep care solutions.
Sagar Chopra
Sahil Chopra
✨
Eli Dorf explains how Bask Health enables rapid telehealth startup launches.
Eli Dorf
✨
Brian Birnbaum analyzes Hims & Hers Q1 earnings and the bull case.
Brian Birnbaum
✨
Mansi Hukmani explores the growing peptide culture and telehealth frontier.
Mansi Hukmani
✨
Enhanced Games co-founders discuss their approach to PEDs and upcoming games.
Christian Angermayer
Max Martin
✨
Analyst David Maris revisits Hims' GLP-1 timeline and Novo partnership.
David Maris